 Patent Application Title |
Patent App Num. |
Date |
| Fast emulation of mac table flushing for elan unicasts | 20100040060 | 20100218 | | According to one general aspect, an apparatus may include a plurality of ports, a port forwarding processor, and a queue controller. In some embodiments, the plurality of ports may be configured to receive and forward packets within a communications network. In various embodiments, the port forwarding processor may be configured to determine a destination port associated with a received packet. In one embodiment, the queue controller may be configured to define at least one emulated local area network (ELAN) via a respective service member set that identifies which ports are members of the service member set, determine whether or not the destination port is a permitted member of the service member set, and, if the destination port associated with the received packet is not a permitted... | | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | 20110015437 | 20110120 | | The present invention relates to the use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is H or OH; R1, R2, R3, R4 and R5 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups such as alkoxy having 1-5 carbon atoms or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoroalkyl or amide; alkylamino, benzoyloxy, nitroxy, phenyl or sulpho; and the pharmacologically active salts thereof.
... | | Heterocyclic compound | 20110015225 | 20110120 | | wherein each symbol is as defined in the specification, or a salt thereof.
... | | Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism | 20110015198 | 20110120 | | Wherein R1a, R1b, R2a, R2b, R3a, and R3b independently represent a hydrogen atom or the like, R4 represents a hydrogen atom, C1-6 alkyl, or the like, R5 represents a hydrogen atom or the like, Z represents C1-6 alkyl or the like, or R4 and Z together form a 4- to 6-membered nitrogen-containing hetero ring, Y1 represents H or the like, Y2 represents H, or Y1 and Y2 together form —O—CH2—, W represents C, SO, or the like, Ar1 represents 6-membered aryl or the like, Ar2 represents 6-membered aryl or the like, and ring A represents a benzene ring, a pyridine ring, or the like.
... | | Mcam modulation and uses thereof | 20110014183 | 20110120 | | Methods, uses, agents and compositions useful for the diagnosis, prevention and/or treatment of inflammatory conditions, such as neuroinflammatory conditions such as multiple sclerosis, and for the identification and selection of inflammatory cytokine-secreting T cell or a precursor thereof, based on the expression and/or modulation of melanoma cell adhesion molecule (MCAM) are disclosed.
... | Subscribe to updates on this page: Elan RSS  | | Apparatus for skin imaging, system for skin analysis | 20110013006 | 20110120 | | The invention relates to an apparatus for skin imaging, a system for skin analysis and a method for skin analysis, using a combination of near-field and far-field skin images under different angles of illumination. The apparatus provides a tool that may be employed for rapid screening of the skin for lesions that may be indicative of skin diseases, in particular skin cancers such as melanoma.
... | | Composition, method and system for making high whiteness inkjet media | 20110012970 | 20110120 | | The present application relates to a surface treatment composition for inkjet media, including: starch; fluorescence whitening agent selected from the group consisting of nonionic, cationic, and anionic fluorescence whitening agents, and combinations thereof; metallic salt including cation and anion, the cations being selected from monovalent metal ions, multiple valent metal ions, and combinations and derivatives thereof, and the anions being selected from the group consisting of fluoride, chloride, iodide, bromide, nitrate, phosphate, chlorate, acetate, and combinations and derivatives thereof; and chemical chelant. The application also relates to a method of making surface-treated inkjet media, including providing a base stock including cellulose paper and applying a surface treatment composition to the base stock. The application also relates to a paper coated with the surface treatment composition and... | | Wireless tracking and monitoring electronic seal | 20110012731 | 20110120 | | An electronic security seal (e-Seal) is disclosed. The e-Seal monitors security of shipments including intermodal containers, reports tampers in real-time, monitors environmental status of goods and reports exceptions in real-time, and reports the location of the shipment with high frequency. The security monitoring complies with the ISO 17712 standard, adding electronic real-time reporting of tamper time and location and LED tamper indication. The e-Seal can be manufactured and operated at low cost due to diagnostic and logistic features. The e-Seal supports low cost upgrades due to a modular architecture allowing a plug-in update of separate functions. The e-Seal allows flexible usage across supply chain tradelanes, due to highly programmable operation including over-the-air remote programming via wireless communications. The e-Seal provides low power operation to save battery... | | Rnai probes targeting cancer-related proteins | 20110009472 | 20110113 | | RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual,... | | N-alkylated cyclic peptide melanocortin agonists | 20110009341 | 20110113 | | where R1, R2, R3, R4a, R4b, R5, R6, R7a, R7b, x, y and z are as defined in the specification, and a method of treating sexual dysfunction, including male erectile dysfunction and female sexual dysfunction, and other melanocortin 4 receptor responsive conditions and disorders.
... | | Methods and reagents for the early detection of melanoma | 20110009288 | 20110113 | | An assay for identifying early stage malignant melanocyte in biopsy tissues is provided by determining whether differential expression of a particular gene indicative of melanoma exceed a cut-off value.
... | | Methods of skin whitening and of screening skin-spot-formation inhibiting and/or skin-spot removing factor | 20110008273 | 20110113 | | A method of skin whitening is provided which includes: selectively activating proliferation and/or differentiation of melanin-containing keratinocytes of the skin.
... | | Honeycomb coating melanin lens and manufacturing process thereof | 20110007265 | 20110113 | | The present invention provides a honeycomb coating melanin lens and a manufacturing process thereof, wherein, it is an optical lens that has honeycomb pattern printed on a surface of a melanin lens and the two sides of the lens are respectively coated with a blue coating and a gold coating. The honeycomb pattern can also adopt other geometric configurations that are arrayed uniformly, and the pattern is printed with a covering paint (water-soluble resin). The present invention adopts the method of first printing honeycomb pattern on the surface of the melanin lens and then coating by vacuum plating to obtain the honeycomb coating melanin lens; the manufacturing process has good stability, low cost and good quality. Not only the lens can isolate the computer radiate and... | Subscribe to updates on this page: Elan RSS | | Agents, compositions and devices for temporary coloring local hair areas | 20110005538 | 20110113 | | Hair-coloring applicators comprising a shield to protect the scalp, polymers of tannic acid having iron ions bound thereto, hair-coloring compositions comprising same and/or melanoidin, and novel alcohol-free carriers, are disclosed, as well uses thereof for coloring hair.
... | | Nicotiana diversity | 20110005536 | 20110113 | | Nicotiana repanda, Nicotiana rosulata, Nicotiana rosulata subsp. ingulba, Nicotiana rotundifolia, Nicotiana setchellii, Nicotiana simulans, Nicotiana solanifolia, Nicotiana spegazzinii, Nicotiana stocktonii, Nicotiana suaveolens, Nicotiana sylvestris, Nicotiana thyrs flora, Nicotiana tomentosa, Nicotiana tomentosiformis, Nicotiana trigonophylla, Nicotiana umbratica, Nicotiana undulata, Nicotiana velutina, Nicotiana wigandioides, and Nicotiana x sanderae.
... |
| Whitening agent and skin external preparation | 20110003838 | 20110106 | | wherein, R1, R3, R4, and R6 are each independently C1-3 alkyl; and R2 and R5 are each independently a hydrogen atom or C1-3 alkyl.
... | | Whitening agent and skin external preparation | 20110003817 | 20110106 | | wherein X1, X2, and X3 are each CR2 or N; R1, R2, and R3 are each H, C1-6 alkyl, C1-6 alkoxy, SH, OH, or NRbRc, wherein Rb and Rc are each H, C1-6 alkyl, or hydroxy-C1-6 alkyl, or NRbRc forms a saturated or unsaturated 5- or 6-membered hetero ring; and B is a substituted or unsubstituted pyrazole, imidazole, pyridine, or piperidine; with the proviso that at least one of R1, R3, R4, and R6 is a group other than C1-3 alkyl in the case where X1═X2═Y1═N and X3═CR2.
... | | Non-basic melanin concentrating hormone receptor-1 antagonists and methods | 20110003759 | 20110106 | | Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.
... | | Vaccine compositions | 20110002898 | 20110106 | | The invention relates to tumour therapy. In particular, the present invention relates to vaccine compositions comprising allogenic cells modified with hypercytokines for the treatment of cancer in general and for the treatment of melanoma in particular.
... | | Vehicle identification, tracking and enforcement system | 20100332394 | 20101230 | | A system for monitoring and tracking vehicles in parking locations, public roadways and highway entrances and exits and other public vehicle access areas is provided, such as to monitor and track vehicles in parking spaces, public roadways and highways without the need for parking or traffic personnel. The system includes a meter system that generates image data of a vehicle in a parking space, public roadway and highway entrances and exits such as by creating an array of pixel data in a predetermined field of view that includes a vehicle identification tag and facial imaging. An enforcement and tracking system receives the image data and generates a vehicle license number, vehicle tag identification number and facial image from the image data, such as by analyzing the... | | Dna markers for management of cancer | 20100330567 | 20101230 | | A method is provided for assessing allelic losses and hypermethylation of genes in CpG tumor promotor region on specific chromosomal regions in cancer patients, including melanoma, neuroblastoma breast, colorectal, and prostate cancer patients. The method relies on the evidence that free DNA and hypermethylation of genes in CpG tumor promotor region may be identified in the bone marrow, serum, plasma, and tumor tissue samples of cancer patients. Methods of melanoma, neuroblastoma, colorectal cancer, breast cancer and prostate cancer detection, staging, and prognosis are also provided.
... | | Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4) | 20100330093 | 20101230 | | Melanoma or a metastasis thereof is treated in a human patient in a combination therapy which includes administering a melanoma-treating combination to a human melanoma patient during a treatment regimen, the combination including an alpha thymosin peptide and antibodies against cytotoxic T lymphocyte-associated antigen 4 (CTLA4).
... | | Av system with skin care and health care functions | 20100324624 | 20101223 | | This specification discloses an AV system with the skin care and health care functions. An AV system and a pulse current generator are integrated. A conductor transmits a pulse current output from the pulse current generator to a human body. The pulse current cures or alleviates the user in pain, melancholy, anxiety, and insomnia, accelerates the recovery of wound or bone, and reduces the side effects of radiotherapy and chemotherapy.
... | | Compositions and methods of use for modulators of polypeptides and polynucleotides in treating breast cancer and melanoma | 20100324270 | 20101223 | | This invention relates to the polynucleotides and the encoded polypeptides, including novel sequences, of human or non-human primate genes that are amplified in breast and/or other tumor tissues melanoma, as compared to the corresponding normal tissue. The invention also relates to modulators of such polynucleotides and polypeptides, for example, antibodies, that specifically bind to and/or interfere with the activity of this polypeptide, polynucleotide, its fragments, variants, and antagonists. The invention further relates to compositions containing such a polypeptide, polynucleotide, or modulators thereof and uses of such compositions in methods of treating or preventing cancer, by detecting this polynucleotide, polypeptide, or antibodies thereto in patient samples. The invention also provides diagnostic tests for breast cancer and melanoma, by identifying polypeptides and polynucleotides encoded by the cDNA sequence... | | Whitening agent and skin external preparation | 20100324096 | 20101223 | | wherein A is C1-6 alkyl, C5-6 cycloalkyl, benzyl, benzylcarbonyl, benzoyl, phenyl, pyridyl or pyrimidyl; Ra is H, C1-6 alkyl, or C2-6 alkenyl; “” represents a single bond or a double bond wherein n=1 or 2; Y is S or O; and R3 and R4 are each independently H, C1-6 alkyl, hydroxy-C1-6 alkyl, C2-7 acyl, phenyl, pyridyl, pyrimidyl, etc.;with the proviso that at least one R3 is a group other than C1-3 alkyl in the case where: the hetero ring containing Y is a thiazoline ring; R4═Ra═H; X1═X2═CH; and either p =0 or R5═C1-6 alkyl.
... | | Diaryl ketimine derivative having antagonism against melanin-concentrating hormone receptor | 20100324049 | 20101223 | | wherein R1a and R1b independently represent a hydrogen atom or a C1-6 alkyl group; R2a, R2b, R3a and R3b independently represent a hydrogen atom, a C1-6 alkyl group, or the like; Y represents H or —OH; Z represents —OR8, or the like; R8 represents a hydrogen atom, a C1-6 alkyl group which may have a substituent, or the like; R9a and R9b independently represent a hydrogen atom, a C1-6 alkyl group, or the like; Ar1 represents an aromatic carbon ring group, or an aromatic heteroring group; Ar2 represents a group produced by removing two hydrogen atoms from an aromatic carbon ring, or the like; and the ring group A represents an unsaturated heteroring group.
... | | Raf kinase modulators and methods of use | 20100324047 | 20101223 | | The present invention comprises a new class of compounds capable of modulating the activity of Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula (I) wherein each of A1, A2, A3, A4, A5, A6, A7, A8, A9, bond B, X, rings Z1 and Z2, R1 and R3 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.
... | | Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists | 20100324036 | 20101223 | | The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin 4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cachexia induced by e.g. cancer, chronic kidney disease (CKD) or chronic heart failure (CHF), muscle wasting, anorexia induced by e.g. chemotherapy or radiotherapy, anorexia nervosa, amyotrophic lateral sclerosis (ALS), pain, neuropathic pain, anxiety and depression.
... | | Use of beta-melanotropin as a therapeutic agent, eg for the treatment of aids or alzheimer | 20100323950 | 20101223 | | The present invention is directed to the use of the peptide compound Ala-Glu-Lys-Lys-Asp-Glu-Gly-Pro-Tyr-Arg-Met-Glu-His-Phe-Arg-Trp-Gly-Ser-Pro-Pro-Lys-Asp-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Ala-Glu-Lys-Lys-Asp-Glu-Gly-Pro-Tyr-Arg-Met-Glu-His-Phe-Arg-Trp-Gly-Ser-Pro-Pro-Lys-Asp-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
... | | Liquid hand dishwashing detergent composition | 20100323943 | 20101223 | | A hand dishwashing detergent composition comprising a chelant and a specific surfactant system to provide superior grease cleaning and shine.
... | | Liquid hand dishwashing detergent composition | 20100323942 | 20101223 | | A hand dishwashing detergent composition comprising a chelant and branched surfactants to provide superior grease cleaning and shine.
... | | Radiosynthesis as an alternative energy utilization process in melanized organisms and uses thereof | 20090328258 | 20091231 | | This present invention provides methods of enhancing the growth of a microorganism or plant by increasing its melanin content and exposing it to radiation, and methods of using melanized microorganisms to contain or exclude radiation.
... | | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators | 20090325990 | 20091231 | | Certain novel N-acylated spiropiperidine derivatives are ligands of the human melanocortin receptor(s) and, in particular, are selective ligands of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of MC-4R, such as obesity, diabetes, nicotine addiction, alcoholism, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
... | | Imidazo[4, 5-b]pyridin-2-one and oxazolo[4, 5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds | 20090325945 | 20091231 | | The present invention pertains to certain imidazo[4,5-b]pyridin-2-one and oxazolo[4,5 b]pyridin-2-one compounds and analogs thereof, which, inter alia, inhibit RAF (e.g., B RAF) activity, inhibit cell proliferation, treat cancer, etc., and more particularly to compounds of the formulae: wherein: J is independently —O— or —NRN1−; RN1, if present, is independently —H or a substituent; RN2 is independently —H or a substituent; Y is independently —CH═ or —N═; Q is independently —(CH2)j-M-(CH2)k— wherein: j is independently 0, 1 or 2; k is independently 0, 1, or 2; j+k is 0, 1, or 2; M is independently O—, —S—, —NH—, —NMe-, or —CH2—; each of RP1, RP2, RP5, and RP4 is independently —H or a substituent; and additionally RP1 and RP2 taken together may be CH═CH—CH═CH—; and additionally RP1... | | Antimicrobial flavouring composition | 20090324515 | 20091231 | | A flavouring composition for use in an oral care product, confectionary product or beverage. The composition includes an antimicrobial key and optionally at least one flavouring ingredient of current use, wherein the antimicrobial key comprises 3,4-dimethylphenol together with one or more antimicrobial flavour ingredients each having a minimum inhibitory concentration of 1000 parts per million or less, against two or more strains selected from Fusobacterium Nucleatum, Fusobacterium sp., Porphyromonas Gingivalis, Prevotella Intermedia, Klebsiella Pneumoniae, Veillonella Alcalescens, Bacteroides Melaninogenicus/forsythus, Selenomonas Sputagena, Porphyromonas Endodontalis, Prevotella Melaninogenica and Streptococcus Mutans.
... | | Laminated body for optical purposes that includes a melanin-containing layer and an optical product which includes the laminate | 20090323179 | 20091231 | | A laminated body of the present invention includes a melanin-containing layer, wherein the melanin-containing layer is formed by curing a composition that includes at least a melanin, a polymerizable monomer, and a urethane-derived composition. The composition for the laminated body of the present invention is used for producing the laminated body and includes at least a melanin, a polymerizable monomer, and a urethane-derived composition. The optical product of the present invention is formed including the laminated body.
... | | Anti-hemorrhage medication pack | 20090318361 | 20091224 | | An anti-hemorrhage medication pack for administering an anti-hemorrhage drug, in particular for the treatment of hemorrhage caused by trauma in emergency situations comprises an active ingredient selected from the group comprising the 1-24 amino acid sequence of the adrenocorticotropic hormone (ACTH 1-24) and all its fragments and analogues, and analogues of fragments, with agonist activity on the MC4 melanocortin receptors, and all the synthesis agonists, including those with a nonpeptidic structure, of the MC4 melanocortin receptors. An auto-injector (1; 11) includes the drug for automatically injecting a patient with the drug.
... | | Recombinant adenylate cyclase of bordetella sp. for diagnostic and immunomonitoring uses, method of diagnosing or immunomonitoring using said recombinant adenylate cyclase, and kit for diagnosing or immunomonitoring comprising said recombinant adenylate c | 20090317854 | 20091224 | | Diagnostic testing and immunomonitoring that uses genetically detoxified Bordetella pertussis CyaA as a delivery system are effective in tracking any immune responses, such as those generated by infectious and non-infectious diseases, or vaccinations, for example. T cells previously stimulated by a given antigen can be restimulated in vitro by the same antigen fused or chemically coupled to CyaA or a fragment thereof. The invention includes diagnostic tests and immunomonitoring for tuberculosis by providing a delivery system, which can deliver the M. tuberculosis immunodominant proteins ESAT-6 and CFP-10, to human cells and non-human animal cells, such as cattle. In addition, fusion proteins between CyaA and cancer antigens are also provided as diagnostic tests and immunomonitoring systems for cancers, such as melanoma.
... | | Process for producing melanin, melanin produced by the process, functional film containing the melanin, and process for producing the same | 20090317616 | 20091224 | | The method for producing a melanin of the present invention, comprises, at least, under controlled conditions, a step for an oxidative reaction wherein a melanin precursor is continuously oxidized while the mole ratio of the melanin precursor relative to the oxidative agent is maintained at a constant ratio, and a step for precipitation wherein a melanin is precipitated by acidifying a reaction solution after the step for an oxidative reaction.
... | | Radiation detector with isolated pixels photosensitive array for ct and other imaging applications | 20090314947 | 20091224 | | This invention describes an imaging system based on an array of semiconductor photosensitive elements with isolating structure between elements (pixels) of the array. The isolated pixels of the array may be photodiodes and they provide excellent imaging capabilities that are important for many applications. The isolated photosensitive pixels may be comprised also by photoconductors, avalanche photodiodes, photosensitive IC, or other similar solid-state devices. The fields of possible application include but are not limited to the detector modules for homeland security, medical imaging systems (CT, SPECT, and PET including), fundamental and applied research, etc.
... | | Pharmacological chaperones for treating obesity | 20090312345 | 20091217 | | The invention relates to methods of enhancing normal melanocortin-4 receptor (MC4R) activity, and to enhancing activity of an MC4R having a mutation which affects protein folding and/or processing of the MC4R. The invention provides a method of treating an individual having a condition in which increased activity of an MC4R at the cell surface would be beneficial, for example in obesity, by administering an effective amount of a pharmacological chaperone for the MC4R. The invention provides MC4R pharmacological chaperones which enhance the activity of MC4R. The invention further provides a method of screening to identify pharmacological chaperones which enhance folding of an MC4R in the endoplasmic reticulum (ER), in order to enhance the activity of the MC4R at the cell surface.
... | | Materials and methods directed to asparagine synthetase and asparaginase therapies | 20090311233 | 20091217 | | Materials and Methods for use in treating cell proliferative disorders related to asparagine metabolism are provided. Cell proliferative disorders include such cancers as forms of leukemia, ovarian cancers, melanomas, renal cancers, breast cancers, brain cancers, and other cancers. Methods include the use of RNA interference targeted at asparagine synthetase to enhance the efficacy of L-asparaginase therapies.
... | | Compounds and methods for kinase modulation, and indications therefor | 20090306087 | 20091210 | | Compounds and salts thereof, formulations thereof conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one Raf protein kinase. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of Raf protein kinases, including melanoma, colorectal cancer, thyroid cancer, ovarian cancer, cholangiocarcinoma, pain or polycystic kidney disease.
... | | Melanocortin receptor-specific peptides for treatment of obesity / 669 | 20090305960 | 20091210 | | where R1, R2, R3, R4, x and y are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes, including obesity, diabetes, modulation of feeding behavior and related metabolic syndrome.
... | | Cyclopeptide with anti-cancer activity derived from collagen type iv | 20090305955 | 20091210 | | The present invention relates to a cyclopeptide characterized in that it comprises the YSNS amino acid sequence, and more particularly a cyclopentapeptide which forms a β-bend structure at the YSNS amino acids. In one specific embodiment, the cyclopeptide of the invention is capable of binding to the αVβ3-integrin. The application also claims the use of a cyclopeptide of the invention in the treatment of cancer, and more particularly in the treatment of the various forms of melanoma, and also in the manufacture of a medicament for treating cancer. Finally, the application describes the use of a cyclopeptide of the invention for inhibiting or reducing angiogenesis, and more particularly in tumours, and also in the manufacture of a medicament for inhibiting or reducing angiogenesis.
... | | Cell therapy method for the treatment of tumors | 20090305418 | 20091210 | | T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate, stimulate and expand naïve cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors, capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen presenting cells (AAPCs; Drosophila melanogaster) transfected with human HLA class I and defined accessory molecules, are used to stimulate CD8+ T cells from both normal donors and cancer patients. The class I molecules expressed to a high density on the surface of the Drosophila cells are empty, allowing for efficient loading of multiple peptides that results in the generation of polyclonal responses recognizing tumor cells endogenously expressing the specific peptides. The responses generated are robust, antigen-specific and... | | Tricyclic compounds as melanogenesis modifiers and uses thereof | 20090304615 | 20091210 | | The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to aberrant melanogenesis activity including by way of non-limiting example, hyperpigmentation and others.
... | | Tannin polymers, processes of preparation and use thereof | 20090304610 | 20091210 | | The invention concerns synthetic polymers obtainable by oxidative polymerization of vegetal tannins, alone or in combination with eumelanin and/or pyrocatechic precursors, method of preparation and uses thereof in the cosmetic and dermato-logic fields; complexes of said polymers with metals and their use in dyeing processes are also disclosed.
... | | Chelating agent conjugated alpha-msh peptide derivatives, preparation method thereof and composition for diagnosis and treatment of melanoma comprising the same as an active ingredient | 20090304586 | 20091210 | | Disclosed are chelating agent-conjugated α-MSH peptide derivatives, preparation methods thereof, and compositions for use in a diagnosis or treatment of a melanoma tumor containing the same as an active ingredient. The novel α-MSH peptide derivatives conjugated with chelating agent according to the present invention are highly selective to the melanocortin-1 receptor which is α-MSH receptor expressing in melanoma tumor and their labeling rate of a radioactive isotope is high. Also, they remain in kidney shortly and have high taking rate of the melanoma tumor. Therefore, with the aforesaid reasons, they may be effectively used for early diagnosis or treatment of melanoma tumor.
... | | Anticorrosive composition | 20090302276 | 20091210 | | The present invention relates to the discovery that melanoidins, and higher molecular weight fractions of products containing melanoidins, provide significant corrosive inhibition, which render these melanoidins suitable for use as anticorrosive agents in corrosive environments. In addition to being highly anticorrosive, the melanoidins of the present invention are environmentally friendly and non-toxic, and can be found in animal food and in human foodstuffs.
... | | Quinoline compounds as melanogenesis modifiers and uses thereof | 20090298868 | 20091203 | | The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to aberrant melanogenesis activity including by way of non-limiting example, pigmentation deficiencies (albinism) and hyperpigmentation and others.
... | | Melanocortin receptor agonists | 20090298829 | 20091203 | | The present invention relates to a compound of the following formula 1, pharmaceutically acceptable salt and isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.
... | | Hydroxy substituted thieno pyrimidinones as melanin concentrating hormone receptor-1 antagonists | 20090298794 | 20091203 | | The present invention provides compounds having the following Formula IA and IB, which are useful as MCHR1 antagonists, and includes prodrugs and pharmaceutically acceptable salts thereof:
... | | Detection and treatment of cancers | 20090298766 | 20091203 | | The present invention relates to methods and compositions for the detection and treatment of melanoma and skin cancers. More particularly, the invention discloses that BCSC-1 expression is altered in melanoma and skin cancer cells, allowing the design of effective detection methods and kits for such conditions. The invention also shows that restoring or increasing expression of BCSC-1 in melanoma and skin cancer cells suppresses tumorigenicity and represents a novel and effective approach for the treatment of melanoma and skin cancers. The invention may be used to detect the presence, stage or type of melanoma and skin cancers, as well as any predisposition thereto. The invention may be used in any mammalian subject, particularly human subjects.
... | | Aplidine treatment of cancers | 20090298752 | 20091203 | | Aplidine demonstrates considerable promise in phase (I) clinical trials for treatment of tumors, and various dosing regimes are given. Tumor reduction has been observed in several tumor types including renal carcinoma, colorectal cancer, lung carcinoid, medullary thyroid carcinomas and melanoma. It has also been found that aplidine has a role in inhibiting angiogenesis, complementing the anti-tumor activity.
... | | Peptide analogs of alpha-melanocyte stimulating hormone | 20090297444 | 20091203 | | Provided herein are stable peptide analogs of the native alpha-melanocyte stimulating hormone (α-MSH) having selectivity for the melanocortin 1 receptor (MC1R). Also provided herein are pharmaceutical preparations of the α-MSH peptide analogs, as well as methods of using these analogs in the treatment of medical and veterinary conditions involving MC1R.
... | | Mid-infrared fiber laser using cascaded raman wavelength shifting | 20090296743 | 20091203 | | A mid-infrared system for optical probing is disclosed that comprises a mid-infrared fiber laser based on cascaded Raman wavelength shifting, a sample volume, and a detector or detection system. The cascaded Raman wavelength shifting process in optical fibers involves the emission of a plurality of optical phonons for at least some of the pump photonics involved in the process. As one example, using the cascaded Raman wavelength shifting process a pump laser wavelength between 1 and 2 μm can be shifted down to between 2.5 to 10 μm. In one embodiment, the mid-infrared fiber laser comprises a pump laser with a wavelength between 1 and 2 μm, one or more stages of cascaded Raman oscillators implemented in fused silica fiber, and one or more stages of... | | Dicarbonic acid derivatives, metastasis inhibitors and agents increasing chemotherapeutic activity of anti-tumor preparations, method for enhancing the cytostatic efficiency and metastasis process inhibiting method | 20090292018 | 20091126 | | The claimed compounds can be used in medical practice as low-toxic agents for enhancing anti-tumor and anti-metastasis effects of known cytostatics with a simultaneous 4-fold reduction of the therapeutic dose of cytostatics. The use of the proposed compounds in a combination with cisplatin at the minimum doses makes it possible to completely inhibit the metastasis process in experimental B-16 melanoma. Furthermore, the use of the proposed compounds at the minimum doses in a combination with the minimum doses of cytostatics (when neither of the preparations alone exhibitsefficacy) makes it possible to obtain a high therapeutic effect in treating leukemias (survival of animals with P-388 leukemia in the test group is 100%).
... | | Composition for treating cancer comprising adult stem cell culture or its fraction | 20090291067 | 20091126 | | The present invention provides a pharmaceutical composition for treating cancer, comprising a culture of adult stem cells or a fraction of the culture as an active ingredient. The culture of adult stem cells and its fraction, especially a specific fraction of adult stem cell culture, inhibit proliferation of a variety of cancer such as melanoma, pancreatic cancer, breast cancer, hepatic cancer, gastric cancer, colon cancer, lung cancer, and cervical cancer, thereby having excellent cancer-treating activity. The composition according to the present invention includes, not stem cells, but a complex of active proteins secreted from the stem cells, and thus both pharmaceutical problems in formulation and individual variation, which usually occurred when using stem cells, can be minimized. And also, side effects caused by direct administration of... | | Treatment of hiv | 20090291060 | 20091126 | | We describe methods of treatment of HIV using proopiomelanocortin (POMC) and corticotropin releasing factor (CRF) peptides and their products, as well as uses of such peptides in the preparation of medicaments.
... | | Compounds and methods for kinase modulation, and indications therefor | 20090286783 | 20091119 | | Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof derivatives thereof, forms thereof are active on at least one Raf protein kinase. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of Raf protein kinases, including melanoma, colorectal cancer, thyroid cancer, ovarian cancer, cholangiocarcinoma, pain or polycystic kidney disease.
... | | Composition for skin care and method for the same | 20080311059 | 20081218 | | A skin whitening composition and a method for the same are provided. The skin whitening composition comprises a far-infrared ray releasing substance having a primary component of an oxide mineral, wherein the skin whitening composition achieves a whitening effect via an irradiation of the far-infrared ray releasing substance. In another aspect, the method comprises the steps of administering a far-infrared ray releasing substance to a subject and reducing melanogenesis of the subject by inhibiting growth of a pigment cell, wherein the far-infrared releasing substance has an oxide mineral.
... | | Methods of inducing melanogenesis in a subject | 20080305152 | 20081211 | | Described herein are methods and compositions for inducing melanogenesis in a human subject. The method comprises administering to a subject an alpha-MSH analogue, in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of subject without inducing homologous desensitization of the melanocortin-1 receptors.
... | | Peptides for use in the treatment of obesity | 20080306008 | 20081211 | | The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
... | | Heterocyclic mchr1 antagonists and their use in therapy | 20080306055 | 20081211 | | Compounds of formula I depicted below, pharmaceutical compositions containing them, processes for preparing the compounds, and their use in the treatment of obesity, type II diabetes, metabolic syndrome, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy and related conditions, neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease, and pain related disorders. The compounds are melanin concentrating hormone receptor 1 (MCHr1) antagonists.
... | | Treatment of melanoma with alpha thymosin peptides | 20080300166 | 20081204 | | A method of treating melanoma or a metastasis thereof in a human patient by administering a melanoma-treating effective amount of an alpha thymosin peptide to a human melanoma patient, wherein the human melanoma patient does not have a substantially elevated LDH blood level.
... | | High affinity melan-a t cell receptors | 20080292549 | 20081127 | | The present invention provides TCRs having an affinity (KD) of less than or equal to 3 μM, and/or an off-rate (koff) of 1×10−3 S−1 or slower, for the AAGIGILTV-HLA-A*0201 complex. Such TCRs are useful, either alone or associated with a therapeutic agent, for targeting cancer cells presenting that complex.
... | | Melanoma antigens and their use in diagnostic and therapeutic methods | 20080292647 | 20081127 | | The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.
... | | Electrolytic water and process for production thereof | 20080292716 | 20081127 | | The present invention discloses a process for producing an electrolytic water, wherein a to-be-electrolyzed water containing less than 0.1 mM of a water-soluble inorganic salt, 0.05 to 0.5 mass % of a hydroquinone derivative and 1 to 50 mM of L-ascorbic acid or a derivative thereof is fed into a diaphragm-free electrolytic cell of continuous flow type at a flow rate of 5 to 3,000 l/min and electrolysis is conducted continuously at a current density of 0.003 to 0.1 A/cm2. The process can produce an electrolytic water having a high skin-whitening effect owing to the reducing action of L-ascorbic acid and the melanin formation-suppressing effect of hydroquinone derivative.
... | | Composition containing beta-glucan, method of producing the same and foods, drinks or skin moisturizers containing the composition | 20080293669 | 20081127 | | It is intended to utilize β-glucan produced by a bacterium belonging to Aureobasidium sp. From a bacterium belonging to Aureobasidium sp., a mutant with little pigment accumulation is constructed by a mutagenesis means of, for example, irradiating with ultraviolet light or treating with a mutagen. A culture obtained by culturing this mutant in a liquid culture medium is usable as a composition with a large β-glucan content without showing any intense dark green color caused by the accumulation of melanin-like pigments. This composition may be taken as such as a functional food having the physiologically active functions of the β-glucan-containing composition. Alternatively, it may be added to foods, drinks. food additives, cosmetics and so on.
... | | Dendritic cells loaded with heat shocked melanoma cell bodies | 20080286314 | 20081120 | | The present invention includes compositions and methods for the isolation, purification and preparation of immunogenic antigens for the production of customized cancer vaccines that include dendritic cells that are contacted with an antigen that includes heat-shocked cancer cells.
... | | Melanoma antigens and their use in diagnostic and therapeutic methods | 20080286804 | 20081120 | | The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.
... | | Use of iontophoresis and ultrasound to deliver melanin or other chromophores for laser hair removal | 20080287931 | 20081120 | | Additionally, this method discloses the use of iontophoresis together with High Intensity Focused Ultrasound (HIFU) and also Radio Frequency (RF) energy combined with High Intensity Focused Ultrasound (HIFU) to specifically target necrotizing energy doses into the regenerative zones of the hair and accomplish hair removal.
... | | Melanoma antigens and their use in diagnostic and therapeutic methods | 20080289055 | 20081120 | | The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.
... | | Use of halogenated hydroxydiphenyl ether compounds for the treatment of the skin | 20080279794 | 20081113 | | as melanogenesis inhibitors and for lightening the skin.
... | | Methods for treating cancer targeting transglutaminase | 20080279844 | 20081113 | | A method for treating cancer comprising inhibiting transglutaminase activity is provided. Suitable cancer types for which the methods of the present disclosure can be used to treat include, but are not limited to, pancreatic, breast, and ovarian cancers and melanoma. The inhibition of transglutaminase activity may be performed by one or more techniques, including, but not limited to, downregulating transglutaminase expression, inhibiting TG2 translation, or blocking TG2 enzymatic activity, such as with a small molecule inhibitor or intracellular antibody (intrabody).
... | | Induction of immunosuppression by inhibition of atm | 20080279866 | 20081113 | | The present invention is directed to methods of inducing immunosuppression in a patient by administering an inhibitor of the enzyme Ataxia telangiectasia mutated (Atm). The method may be used as a treatment for allergies, autoimmune diseases or lymphomas. It may also be used to prevent organ rejection in transplant patients and to treat or prevent graft versus host disease.
... | | Viral adjuvants | 20080279891 | 20081113 | | The present invention provides viral adjuvants for enhancing an immune response to an immunogen. In particular embodiments, the viral adjuvant is an alphavirus adjuvant or a Venezuelan Equine Encephalitis viral adjuvant. Also provided are compositions comprising the viral adjuvant and an immunogen, and pharmaceutical formulations comprising the viral adjuvant or compositions of the invention in a pharmaceutically acceptable carrier. Further provided are methods of producing an immune response against an immunogen in a subject comprising administering the immunogen and a viral adjuvant of the invention to the subject.
... | | Novel peptides for use in the treatment of obesity | 20080280820 | 20081113 | | The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
... | | Iminosugar treatment of tumors | 20080280972 | 20081113 | | where R and R′ are each alkyl groups, R″ is hydrogen or an alkyl group and X3, X4 and X5 are each independently selected from the group consisting of hydrogen, benzyl, t-butyldimethylsiloxy radical and triphenylmethyl. Accordingly, compounds of formula (I) can be used for treatment of tumors including melanoma. Also a secretion of a matrix metalloproteinase (MMP) enzyme by cells can be reduced by contacting the cells with the compound having formula (I). Accordingly, compounds of formula (I) can be used for treatment physiological conditions associated with an elevated MMP level, such as tumors.
... | | Erythrocytes containing arginine deiminase | 20080274092 | 20081106 | | Use of erythrocytes containing arginine deirainase for the preparation of a medicinal product for lowering the plasma concentration of arginine in vivo. Said use relates in particular to the treatment of arginine-dependent tumors, such as hepatocarcinoma and malignant melanoma, or inhibition of the synthesis of nitric oxide, and the prevention and/or treatment of septic shock.
... | | C-kit oncogene mutations in melanoma | 20080274469 | 20081106 | | The present invention provides methods of detecting c-KIT-dependent-melanoma for diagnostic and prognostic purposes. The invention further provides methods of treating such melanoma by inhibiting c-KIT.
... | | Diagnosis of melanoma by nucleic acid analysis | 20080274908 | 20081106 | | The present invention provides methods for diagnosing melanoma in a subject by analyzing nucleic acid molecules obtained from the subject. The present invention also provides methods for distinguishing melanoma from dysplastic nevi and/or normal pigmented skin. The methods include analyzing expression or mutations in epidermal samples, of one or more skin markers. The methods can include the use of a microarray to analyze gene or protein profiles from a sample.
... | | Rnai probes targeting cancer-related proteins | 20080274996 | 20081106 | | RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual,... | | Pigmentary deposition portion remote diagnosis system | 20080275315 | 20081106 | | A major object of this invention is to provide a remote diagnosis apparatus, a remote diagnosis system, a user terminal, a program, a diagnosis program, and a storage for easily diagnosing a pigmentary deposition portion. A user of the system picks up the skin having benign nevus pigmentosus that might be melanoma through a dermoscope using a portable telephone with a camera to which the dermoscope is attached by means of an adapter, accesses to the Internet using an Internet connection function of the portable telephone, and sends the picked up skin image to the remote diagnosis apparatus. After receiving the skin image, the remote diagnosis apparatus uses the melanoma diagnosis program to examine the skin image for melanoma and a disease stage of melanoma if... | | Non-basic melanin concentrating hormone receptor-1 antagonists | 20080269110 | 20081030 | | where R1, R1a, R1b, A, R3, R4, R5, R5b and R6 are as defined herein.
... | | Melanocortin-4 receptor binding compounds and methods of use thereof | 20080269217 | 20081030 | | wherein L2 is a linker group, and P1, P2, P3, P4, Z1, Z2, Z3, Z4, Z5, t, s, and R are as described in the specification. Methods of using the compounds to treat MC4-R associated disorders, such as disorders associated with weight loss, are also provided.
... | | Kinase inhibitors useful for the treatment of myleoprolific diseases and other proliferative diseases | 20080269254 | 20081030 | | Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant, melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, leukemias, papillary thyroid carcinoma, non small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocyctosis, mast cell leukemia, a disease caused by c-Abl kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, or a disease caused by c-Kit kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof.
... | | Kinase inhibitors useful for the treatment of myleoprolific diseases and other proliferative diseases | 20080269267 | 20081030 | | Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, a disease caused by c-Abl kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, a disease caused by c-Kit kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, a... | | Use of halogenated hydroxydiphenyl ether compounds for the treatment of the skin | 20080260667 | 20081023 | | as melanogenesis inhibitors and for lightening the skin.
... | | Kinase inhibitors useful for the treatment of myleoprolific diseases and other proliferative diseases | 20080261961 | 20081023 | | Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant, melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, leukemias, papillary thyroid carcinoma, non small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocyctosis, mast cell leukemia, a disease caused by c-Abl kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, or a disease caused by c-Kit kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof.
... | | Inhibition of breast carcinoma stem cell growth and metastasis | 20070297983 | 20071227 | | Disclosed is a method for inhibiting the growth of breast carcinoma stem cells. that express High Molecular Weight -Melanoma Associated Antigen (HMW-MAA). The method comprises administering to an individual a composition comprising an antibody reactive with HMW-MAA or a fragment of such an antibody in an amount effective to inhibit the growth of the breast carcinoma cells. Also provided are methods for inhibiting metastasis of breast carcinomas and methods for identifying HMW-MAA+ breast cancer stem cells.
... | | Compositions and methods for tumor-targeted delivery of effector molecules | 20070298012 | 20071227 | | The present application discloses the preparation and use of attenuated tumor-targeted bacteria vectors for the delivery of one or more primary effector molecule(s) to the site of a solid tumor. The primary effector molecule(s) of the invention is used in the methods of the invention to treat a solid tumor cancer such as a carcinoma, melanoma, lymphoma, or sarcoma. The invention relates to the surprising discovery that effector molecules, which may be toxic when administered systemically to a host, can be delivered locally to tumors by attenuated tumor-targeted bacteria with reduced toxicity to the host. The application also discloses to the delivery of one or more optional effector molecule(s) (termed secondary effector molecules) which may be delivered by the attenuated tumor-targeted bacteria in conjunction with the... | | Antisense oligonucleotide to inhibit melanoma inhibitory activity mia | 20070299022 | 20071227 | | An antisense oligonucleotide selected from the group of the sequence 5′-TTG CAT AAA CCC AAG GAG-3′ and modifications thereof a fragment having at least 8 nucleotides of the sequence 5′-TTG CAT AAA CCC AAG GAG-3′ and modifications thereof.
... | | Melanin concentrating hormone antagonists | 20070299062 | 20071227 | | The present invention relates to compounds capable of serving as moderators of human and mammalian appetite and as such provide a means for reducing body mass and controlling obesity.
... | | 2-arylcarboxamide-nitrogenous heterocycle compound | 20070299070 | 20071227 | | [wherein R1 and R2 are the same or different and each represents C1-6 alkyl, C3-8 cycloalkyl, et al; R3a, R3b, and R4 are the same or different and each represents hydrogen, C1-6 alkyl, et al; X represents —N—, —CH—, et al; Y, represents a single bond, C1-3 alkylene, et al; Y2 represents C1-4 alkylene, oxy(C1-4 alkylene), et al; Ar1 represents a monocyclic aromatic carbocyclic group, monocyclic aromatic heterocyclic group, et al; and Ar2 represents a 5- or 6-membered aromatic carbocyclic group, aromatic heterocyclic group, et al]. This compound functions as a melanin-concentrating hormone receptor antagonist and is useful as, e.g., a therapeutic agent for obesity, et al.
... | | Diphenyl ox-indol-2-one compounds and their use in the treatment of cancer | 20070299102 | 20071227 | | wherein at least one of X1 and X2 is a heteroatom substituent, e.g. 6-chloro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one.
... | | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma | 20070292392 | 20071220 | | It is described the use of thymosin alpha in combination with dacarbazine and optionally with Interferon alpha, for preparing a medicament for the treatment of malignant melanoma on stage IV characterized by distant unresectable metastases.
... | | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma | 20070292393 | 20071220 | | It is described the use of thymosin alpha in combination with dacarbazine and optionally with Interferon alpha, for preparing a medicament for the treatment of malignant melanoma on stage IV characterized by distant unresectable metastases.
... | | Treatment of non-neuronal cancer using hsv-1 variants | 20070292394 | 20071220 | | A mutant herpes simplex virus which has been modified in the γ34.5 gene such that the gene is non-functional is used to treat a non-neuronal cancer such as a mesothelioma, ovarian carcinoma, bladder cancer or melanoma. Typically, the mutant herpes simplex virus has been modified within the BamHI restriction fragment of the long terminal repeat of the viral genome.
... | | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (glp)-1 compound or a melanocortin-4 receptor (mc4) agonist peptide | 20070293423 | 20071220 | | The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
... | | Modulators of melanocortin receptor | 20070293498 | 20071220 | | L1, L2, L3 and Q are linker groups, and Rings A, B and C, and R1-R14 are described in the specification. The compounds are antagonists of melanocortin receptors.
... | | Absorbent article having a graphic visible through body contacting surface | 20070293834 | 20071220 | | The invention is directed to an absorbent article, which is preferably a sanitary napkin or a pantiliner, comprising: a body contacting layer; a garment contacting layer; and an absorbent core disposed between the body contacting layer and the garment contacting layer. The absorbent core has a core edge. The core edge defines a core region within the core edge and an outer region outside the core region. The body contacting layer and the garment contacting layer extend outward into the outer region and joined together in the outer region. In one aspect of the invention, the garment contacting layer has a graphic printed on the body facing surface at least in a portion of the outer region. In another aspect of the invention, the body contacting... | | Method of making closure housing for sealing | 20070284132 | 20071213 | | A method is provided for making a closure housing for sealing. The method includes forming a plurality of housings. At least one of the housings is formed as a concave housing with an open face. The method also includes aligning one or more layers, such as for example an elastomeric film or conformable selant, on one or more of the concave housings in a substantially planar configuration across a circumferential perimeter of the open face of each of the concave housings. The method also includes securing the elastomeric films on the circumferential perimeter of the open face of each of the concave housings. The elastomeric films are adapted to interface one or more cables when the cables are interposed between the elastomeric films on the housings.
... | | Use of dicarbonyl compounds for increasing the thermal stability of biopolymers in the field of oil and gas exploration | 20070287638 | 20071213 | | The use of dicarbonyl compounds for increasing the thermal stability of biopolymers in aqueous liquid phases in petroleum and natural gas exploration is claimed. The biopolymer component preferably comprises polysaccharides prepared by fermentation, such as, for example, scleroglucan or welan gum. The aqueous liquid phase is typically a drilling fluid which may also contain high salt concentrations (“brines”). Glyoxal may be mentioned as a particularly suitable member of the dicarbonyls. It can either be admixed with the liquid phase or preferably also be incorporated in the course of the preparation of the biopolymer. The use according to the invention shows their advantages, particularly at temperatures in the rock formation which are above 250° Fahrenheit.
... | | Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds | 20070287838 | 20071213 | | The present invention pertains to certain imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof, which, inter alia, inhibit RAF (e.g., B-RAF) activity, inhibit cell proliferation, treat cancer, etc., and more particularly to compounds of the formula (I): wherein: J is independently —O— or —NRN1—; RN1, if present, is independently —H or a substituent; RN2 is independently —H or a substituent; Y is independently —CH═ or —N═; Q is independently —(CH2)j-M-(CH2)k— wherein: j is independently 0, 1 or 2; k is independently 0, 1, or 2; j+k is 0, 1, or 2; M is independently —O—, —S—, —NH—, —NMe—, or —CH2—; each of RP1, RP2, RP3, and RP4 is independently —H or a substituent; and additionally RP1 and RP2 taken together may be —CH═CH—CH═CH—; L is independently: a... | | Apparatus and method for detecting the presence of radioactive materials | 20070273538 | 20071129 | | A passive radiation sensor suitable for homeland security applications or other monitoring of locations deemed at high risk to radiation exposure. The sensor further incorporates a method to provide a statistically derived detection threshold algorithm that guarantees a predetermined and configurable false-alarm rate and rapid detection of low-level radiation.
... | | Laser system architecture and method of using the same | 20070274353 | 20071129 | | A color dazzle system to enhance area denial to personnel mission for law enforcement, homeland security, border patrol, and the military effectively by interrupting the ability of combatants to continue with their intended mission. The color dazzle system has a multi-wavelength laser module for generate desired color or wavelength ranges of light, a beam projector module for pointing the light towards the target to be dazzled, and a fiber optic beam delivery system for delivering the light to the beam projector module. By adjusting the power output according to the corresponding wavelength and the distance to the target, and quickly switching between the wavelengths of light, a dazzle effect can be obtained with an irradiance within a safety range for the eye.
... | | Compositions for affecting weight loss | 20070275970 | 20071129 | | Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-MSH activity.
... | | Novel diazepine compounds as ligands of the melanocortin 1 and/or 4 receptors | 20070270411 | 20071122 | | There is provided novel diazepines that function as agonists at the melanocortin 4 receptor and as agonists at the melanocortin 1 receptor, pharmaceutical compositions containing them, methods for their use in treatment, and processes for their preparation.
... | | Compositions for affecting weight loss | 20070270450 | 20071122 | | Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-MSH activity.
... | | Light beam wavelength mixing for hair removal | 20070270785 | 20071122 | | A light based treatment method and apparatus removes unwanted hair from a target region of skin. The treatment method uses multiple wavelength bands of light or radiation. The ratio of the energies of the wavelength bands is selected according to a skin parameter, e.g., skin type, which can be differentiated by the amount of melanin in the skin. The treatment method can provide safe and effective permanent hair removal for any skin type.
... | | Skin lightening method | 20070264212 | 20071115 | | A skin lightening composition for lightening the natural skin color of a user, and for treating disorders of hyperpigmentation. The active ingredient is methyl sulfonyl methane (MSM), a naturally occurring sulfur compound which may be safely administered topically or orally and which is highly effective for decreasing the ratio of dark melanin to light melanin, and thereby lightening the skin color of a user. The skin lightening composition additionally comprises a liquid solution or a cosmetic carrier such as a cream, a lotion, or a gel, for ease of topical application. Additionally, the skin lightening composition is provided in liquid or solid form for oral ingestion. Topical preparations of the skin lightening composition contain MSM in an amount equal to approximately 1 to 20 weight percent... | | Cell culture model and applications thereof | 20070264682 | 20071115 | | The present invention relates to a multicellular model comprising at least, as cell type: keratinocytes, melanocytes, and nerve cells, in which the keratinocytes and the melanocytes form a first cell layer, said nerve cells form a second cell layer devoid of physical contact with the first cell layer, said first and second cell layers being arranged so as to be compatible with a manifestation of at least one cellular chemical exchange.
... | | Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor | 20070265204 | 20071115 | | This invention pertains to inhibitors of atrial natriuretic peptide receptor A (NPRA) function, such as small interfering RNA (siRNA), useful for reducing the inflammation associated with many human diseases, such as asthma, respiratory syncytial virus (RSV) infection, and cancers (such as melanoma, lung cancer, and/or ovarian cancer) by interfering with NPRA gene expression or otherwise reducing NPRA function within a subject; and methods for treating a subject suffering from, or at risk of developing, an inflammatory disease, respiratory allergy (such as allergic rhinitis and asthma), viral infection, and/or cancer by administering such NPRA inhibitors to the subject.
... | | Substituted piperazines and methods of use | 20070265248 | 20071115 | | Selected substituted piperazine compounds are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
... | | Melanoma differentiation associated gene - 5 and promoter and uses thereof | 20070259372 | 20071108 | | The invention provides for an isolated nucleic acid encoding Mda-5 (melanoma differentiation associated gene-5) and an isolated Mda-5 polypeptide. The invention further provides a vector comprising the nucleic acid encoding Mda-5, as well as a host cell comprising the vector. The invention provides an antibody which specifically binds to an Mda-5 polypeptide. The invention further provides a method for determining whether a compound is an inducer of Mda-5 gene expression and assays to determine whether a compound modifies the enzymatic activity of the Mda-5 polypeptide.
... | | Melanoma antigens and their use in diagnostic and therapeutic methods | 20070259422 | 20071108 | | The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen-and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.
... | | Remedy for melanoma | 20070259805 | 20071108 | | The present invention was aimed at reducing transcription activating activity of MITF-M to inhibit production of BCL2 gene product and thereby to allow treatment and/or prevention of melanoma The present invention provided a method of inhibiting production of BCL2 gene product and an agent for inhibiting the same, which inhibit binding of protein selected from a group consisting of HLF, ELK4 and CLOCK to MITF-M, a method of inducing cell death of melanoma cells, an agent for inducing the same, an agent for treating and/or preventing diseases accompanied by enhanced production of BCL2 gene product, such as melanoma, a method of treating and/or preventing the diseases, a method of identifying any one of the following compounds: a compound that inhibits the aforementioned binding; a compound that... | | Dihydroxyphenyl isoindolylmethanones | 20070259886 | 20071108 | | are disclosed as inhibits or modulators of the activity of the heat shock protein Hsp90. As such they are useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate cancer, lung cancer, gastrointestinal stromal tumor, breast cancer and melanoma.
... | | Methods of using nonpolar grape seed extracts to stimulate tyrosinase expression or melanin synthesis | 20070254054 | 20071101 | | The present invention relates to methods of increasing tyrosinase synthesis, expression, or activity in a cell comprising administering to the cell at least one non polar grape seed extract, for example, a nonpolar grape seed extract obtained using hexane as an extraction solvent. The nonpolar grape seed extract may be obtained by any extraction process including solvent sequential fractionation and supercritical fluid extraction.
... | | Diagnostic radio frequency identification sensors and applications thereof | 20060290496 | 20061228 | | An integrated passive wireless chip diagnostic sensor system is described that can be interrogated remotely with a wireless device such as a modified cell phone incorporating multi-protocol RFID reader capabilities (such as the emerging Gen-2 standard) or Bluetooth, providing universal easy to use, low cost and immediate quantitative analyses, geolocation and sensor networking capabilities to users of the technology. The present invention can be integrated into various diagnostic platforms and is applicable for use with low power sensors such as thin films, MEMS, electrochemical, thermal, resistive, nano or microfluidic sensor technologies. Applications of the present invention include on-the-spot medical and self-diagnostics on smart skin patches, Point of Care (POC) analyses, food diagnostics, pathogen detection, disease-specific wireless biomarker detection, remote structural stresses detection and sensor networks for... | | Uses of melanocortin-3 receptor (mc3r) agonist peptides | 20060293223 | 20061228 | | The present invention provides methods of treating metabolic disorders, including, for example, obesity, diabetes mellitus, cachexia, sarcopenia, and cardiovascular disorders, methods of inducing weight loss and increasing muscle mass in a patient, by administration of MC3R agonist peptides. Furthermore, the present invention provides the use of an MC3R agonist peptide for the manufacture of a medicament for the treatment of metabolic disorders, including, for example, obesity, diabetes mellitus, cachexia, sarcopenia, and cardiovascular disorders, inducing weight loss and increasing muscle mass in a patient.
... | | Anti-cd71 monoclonal antibodies and uses thereof for treating malignant tumor cells | 20060286030 | 20061221 | | The present invention provides novel anti-CD71 monoclonal antibodies, in particular mouse-human chimeric anti-CD71 monoclonal antibodies, advantageously associated to effector cells for triggering ADCC mechanisms. Anti-CD71 antibodies, as well as pharmaceutical compositions containing them, are useful for inhibiting proliferation and/or killing malignant tumor cells, especially metastatic cutaneous and uveal melanoma cells.
... | | Recombinant adenylate cyclase of bordetella sp. for diagnostic and immunomonitoring uses, method of diagnosing or immunomonitoring using said recombinant adenylate cyclase, and kit for diagnosing or immunomonitoring comprising said recombinant adenylate c | 20060286613 | 20061221 | | Diagnostic testing and immunomonitoring that uses genetically detoxified Bordetella pertussis CyaA as a delivery system are effective in tracking any immune responses, such as those generated by infectious and non-infectious diseases, or vaccinations, for example. T cells previously stimulated by a given antigen can be restimulated in vitro by the same antigen fused or chemically coupled to CyaA or a fragment thereof. The invention includes diagnostic tests and immunomonitoring for tuberculosis by providing a delivery system, which can deliver the M. tuberculosis immunodominant proteins ESAT-6 and CFP-10, to human cells and non-human animal cells, such as cattle. In addition, fusion proteins between CyaA and cancer antigens are also provided as diagnostic tests and immunomonitoring systems for cancers, such as melanoma.
... | | Substituted melanocortin receptor-specific single acyl piperazine compounds | 20060287330 | 20061221 | | and pharmaceutically acceptable salts thereof, where J is a substituted or unsubstituted monocyclic or bicyclic ring structure, W is a heteroatom unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor, Q is a substituted or unsubstituted aromatic carbocyclic ring group, L, R2a, R2b, R3a, R3b, r, x and y are as defined in the specification, and the carbon atoms marked with an asterisk can have any stereochemical configuration. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, including... | | Melanocortin receptor-specific piperazine compounds with diamine groups | 20060287331 | 20061221 | | and pharmaceutically acceptable salts thereof, where W is a diamine heteroatom unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor, J, Q, L1, L2, L3, R1a, R1b, R2a, R2b and X are as defined in the specification, and the carbon atom marked with an asterisk can have any stereochemical configuration. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, including specifically treatment of obesity and related conditions.
... | | Melanocortin receptor-specific piperazine and keto-piperazine compounds | 20060287332 | 20061221 | | and pharmaceutically acceptable salts thereof, where X, W, J, Q, L1, L2, L3, R1a, R1b, R2a, and R2b are as defined in the specification, and the carbon atom marked with an asterisk can have any stereochemical configuration. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, including specifically treatment of obesity and related conditions.
... | | 2-aminoquinoline derivatives | 20060287340 | 20061221 | | [in which R1 and R2 either stand for lower alkyl, lower cycloalkyl, etc., or R1 and R2 together form an aliphatic nitrogen-containing heterocycle with the nitrogen atom to which they bind; R3, R4, R5, R6 and R7 stand for hydrogen, lower alkyl, etc.; R8 stands for lower alkyl, lower alkyloxy, etc.; and n stands for an integer of 0-4]. The compounds act as melanin concentrating hormone receptor antagonist, and are useful as medicines for central nervous system disorders, cardiovascular disorders and metabolic disorders.
... | | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc) | 20060287523 | 20061221 | | This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7-diaminophenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methythioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallisation (RX). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and... | | Food for testing life style-related diseases | 20060280681 | 20061214 | | It is intended to provide a food for testing life style-related diseases which is in the form of a food easy to ingest, differing from the existing medicines such as Trelan G, and makes it possible to simultaneously and easily perform a glucose tolerance test and examine oral glucose tolerance, heperlipemia after meal and so on. Namely, a test food for testing metabolic factors causing life style-related diseases which contains 100 parts by weight of carbohydrate and from 20 to 40 parts by weight of fat. It contains from 73 to 77 g of carbohydrate and from 15 to 30 g of fat, in terms of a single test dose, and provides from 460 to 600 kcal. This test food is usable in testing many items... | | Novel benzimidazole and imidazopyridine derivatives and use thereof as a medicament | 20060281784 | 20061214 | | The invention relates to novel benzimidazole and imidazopyridine derivatives having general formula (I), which have a good affinity with certain sub-types of melanocortin receptors, particularly MC4 receptors. Said derivatives are particularly suitable for the treatment of pathological states and diseases involving one or more melanocortin receptors. The invention also relates to pharmaceutical compositions containing said products.
... | | Light filters using yellow melanin and melanin-like oligomers and photochromic dyes | 20060282066 | 20061214 | | Light filters that use yellow melanin or melanin like materials prepared to have a yellow color and a melanin transmission spectrum in combination with a photochromic dye are disclosed. The yellow form of melanin has minimal impact on the perception of light intensity with transmission values greater than 80%. The combination allows for a single light filter suitable for both night driving and sunglass applications and which also preserve color perception.
... | | Methods of [11c]-radiolabelling phenothiazine and phenothiazine-like compounds | 20060275209 | 20061207 | | This invention pertains to methods of [11C]-radiolabelling “phenothiazine” and “phenothiazine-like” compounds, which have a pendant group (which is a primary amino group; a cationic primary imino group; a secondary amino group; a cationic secondary imino group; a primary imino group; or a secondary imino group), by reaction with [11C]methyl trifluoromethanesulfonate (CF3SO2O11CH3), also known as [11C]methyl triflate. This reaction converts the pendant group into a [11C]methyl-labelled pendant group. The resulting [11C]-radiolabelling product is useful, for example, as an in vivo positron emission tomography (PET) tracer, for example, for patients suffering from melanoma, the most serious form of skin cancer, and tauopathy (e.g., Alzheimer's disease). The present invention also pertains to the resulting [11C]-radiolabelling products, compositions comprising them, their use in methods of (e.g., PET) imaging, their use... | | Antibodies to treat cancer | 20060275307 | 20061207 | | Compositions and methods for the treatment of cancer, particularly melanoma, myeloma, small cell lung cancer, thymic lymphoma, T-cell lymphoma, B-cell lymphoma, osteosarcoma, and acute T-cell leukemia, are disclosed. Illustrative compositions include one or more anti-ganglioside antibodies and polynucleotides that encode such anti-ganglioside antibodies. These antibodies may be for example, hamster antibodies, chimeric human/hamster antibodies, or humanized antibodies. The disclosed compositions are useful, for example, in the treatment of cancer and can be used to induce apoptosis in a cancer cell.
... | | Mobile and wireless network architecture for law enforcement | 20060276200 | 20061207 | | An officer communication system and method for providing a peer-to-peer mobile and wireless network software architecture which allows mobile units or clients, administrators, and/or dispatchers to communicate information that is pertinent to law enforcement, or related services. Such information includes text, images and/or audio. For example, such information can be indicative of an officer's or suspect's location (e.g., latitude, longitude, altitude, or intersection), speed and direction of travel, an officer's assignment details, national or local bulletins, the homeland security alert level, a “live” video feed, maps or directions, etc. In one embodiment, the system via a client user interface allows for the automatic readout of intersections during a chase, and the marking on maps of special locations (e.g. locations where evidence can be found).
... | | Gpi anchored glycoprotein aca as a novel tumor marker | 20060276375 | 20061207 | | Described is a GPI-anchored surface glycoprotein having a GPI-anchor which is characterized by a non-acetylated inositol ring and diacyl glycerol as lipid tail of the anchor. A particular glycoprotein of the invention, ACA, is strongly expressed in melanoma cells, some leukemia cells and other tumor cells, thus, is an useful marker for diagnosis of said tumors. The invention also relates to salts, functional derivatives and active fractions of ACA having substantially the same spectrum of biological activities of ACA. The invention also relates to a process for the purification of ACA, to its cloning and its production by recombinant DNA techniques. It further relates to diagnostic compositions comprising an anti-ACA-antibody or an oliognucleotide probe capable of hybridizing to ACA-mRNA and to pharmaceutical compounds containing a compound... | | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | 20060276485 | 20061207 | | The present invention relates to novel substituted piperidine and piperazine derivatives as melanocortin-4 receptor (MC-4R) modulators. MC-4R agonists of the invention can be used for the treatment of disorders and diseases such as obesity, diabetes, and sexual dysfunction, whereas the MC-4R antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. All diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.
... | | Pharmaceutical use of 1-azabicyclo[2.2.2]octanes and a method of testing compounds for the ability of activating inactive wt p53. | 20060276502 | 20061207 | | The present invention relates to the use of 1-azabicyclo[2.2.2]octanes, capable of transferring wild type p53 from an inactive and non-functional conformation into an active conformation, for the preparation of a pharmaceutical compositions for use in treating medical compositions wherein wt p53 exists in an inactive state defined herein, especially malignant melanoma and conditions involving undesired angiogenesis. The inven-tion also relates to methods of in vivo and in vitro testing of compounds for the above-mentioned ability, wherein inactive wt p53 is monitored or detected.
... | | Automatic detection of critical dermoscopy features for malignant melanoma diagnosis | 20060269111 | 20061130 | | Improved methods for computer-aided analysis of identifying features of skin lesions from digital images of the lesions are provided. Improved preprocessing of the image that 1) eliminates artifacts that occlude or distort skin lesion features and 2) identifies groups of pixels within the skin lesion that represent features and/or facilitate the quantification of features are provided including improved digital hair removal algorithms. Improved methods for analyzing lesion features are also provided.
... | | Extraction of dihydrogen oxide stratagies and solutions | 20060261009 | 20061123 | | A method and product are disclosed for extracting only dihydrogen oxide from subsurface strata containing a currently unusable product, or “MUC” (Matrix Ubiquitous Crude) with no environmental impact. EDOM Extraction of Dihydrogen Oxide Module) will extract water from the currently unusable product, Matrix Ubiquitous Crude for national use, emergencies and homeland security as well as the American public's common good. Extraction of Dihydrogen Oxide Module consists of a single or multiple stage replaceable subterranean module placed within the inside casing of a well casing that facilitates a customized water purification system designed for treatment of each specific quality of Matrix Ubiquitous Crude. The intended ultimate end use of the produced water will determine each Extraction of Dihydrogen Oxide Module's internal composition of customized water treatment components... | | Antibodies to treat cancer | 20060263374 | 20061123 | | Compositions and methods for the treatment of cancer, particularly melanoma, myeloma, small cell lung cancer, thymic lymphoma, T-cell lymphoma, B-cell lymphoma, osteosarcoma, and acute T-cell leukemia, are disclosed. Illustrative compositions include one or more anti-ganglioside antibodies and polynucleotides that encode such anti-ganglioside antibodies. These antibodies may be for example, hamster antibodies, chimeric human/hamster antibodies, or humanized antibodies. The disclosed compositions are useful, for example, in the treatment of cancer and can be used to induce apoptosis in a cancer cell.
... | | Compounds, formulations, and methods for ameliorating telangiectasias | 20060264515 | 20061123 | | Methods, compounds, and topical formulations for treatment of telangiectasias are disclosed. The methods comprise topically applying a composition comprising an α-adrenergic receptor agonist to telangiectatic skin. Amelioration of telangiectasia symptoms begins within minutes after topical application of a disclosed composition. A single application can significantly lessen telangiectasia discoloration for at least about 2 hours.
... | | Novel melanocortin receptor templates, peptides and use thereof | 20060258590 | 20061116 | | The present invention relates to novel chimeric peptides and templates containing a combination of antagonist and agonist endogenous ligand residues. In particular, the present invention relates to novel chimeric peptides and templates thereof based upon melanocortin agonist peptides and agouti related protein (AGRP). The present invention provides multifunctional chimeric peptides having specific bioactivity at melanocortin receptors and their use as drugs to treat various diseases and conditions.
... | | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | 20060258730 | 20061116 | | Selected sulfonic acids, their derivatives and pharmaceutical compositions containing such compounds are useful in inhibiting the chernotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CX-CR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. Notably, the selected sulfonic acids and their derivativas are devoid of cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.
... | | High-sensitivity, high-resolution detector devices and arrays | 20060249747 | 20061109 | | Avalanche amplification structures including electrodes, an avalanche region, a quantifier, an integrator, a governor, and a substrate arranged to detect a weak signal composed of as few as several electrons are presented. Quantifier regulates the avalanche process. Integrator accumulates a signal charge. Governor drains the integrator and controls the quantifier. Avalanche amplifying structures include: normal quantifier, reverse bias designs; normal quantifier, normal bias designs; lateral quantifier, normal bias designs; changeable quantifier, normal bias, adjusting electrode designs; normal quantifier, normal bias, adjusting electrode designs; and lateral quantifier, normal bias, annular integrator designs. Avalanche amplification structures are likewise arranged to provide arrays of multi-channel devices. The described invention is expected to be used within photodetectors, electron amplifiers, chemical and biological sensors, and chemical and biological chips with lab-on-a-chip... | | Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof | 20060251678 | 20061109 | | The present invention provides a Venezuelan equine encephalitis virus replicon RNA useful in the development of stable lines of mammalian, avian and insect cells in which these replicons will persistently replicate. Venezuelan equine encephalitis (VEE) virus replicons contain a number of unique adaptive mutations that make the replicons noncytopathic. The replicons remain resistant to IFN-α/β. Replicon replication leads to high-level production of heterologous proteins, which are encoded by the replicons' genome and are under the control of a viral subgenomic promoter. Also provided are methods of screening for inhibitory compounds of Venezuelan equine encephalitis virus replication and eastern equine encephalitis virus replication.
... | | Alteration of rab38 function to modulate mammalian pigmentation | 20060252036 | 20061109 | | The present invention relates to compositions and methods involving melanocytes. In particular, the present invention provides compositions and methods involving RAB38 and mutant RAB38, suitable for use in modulation of pigmentation and for use in determining the means to diagnose and/or treat conditions associated with disorders in pigmentation.
... | | Deoxynucleoside kinase from insect cells for the synthesis of nucleoside monophosphates | 20060252131 | 20061109 | | Recombinant kinase remaining stable during the synthesis of necleoside monophosphate without the addition of stabilizing SH reagents, without stabilizing proteins and accepting all four natural deoxynucleotides, obtainable from insect cells such as e.g. Drosophila Melanogaster. In addition, the invention concerns DNA sequences, vectors, transformed cells, a method for production of the recombinant kinase as well as its use for preparing nucleoside monophosphates.
... | | Method for reversing the immunosuppressive effects of the melanoma inhibitory activity "mia" | 20060252716 | 20061109 | | A method for stimulating immune cells and/or the immune system, and/or reducing invasion and/or metastasis of tumor cells by inhibiting expression and/or functional activity of “Melanoma Inhibitory Activity” MIA.
... | | Use of antibodies against the muc18 antigen | 20060246077 | 20061102 | | The present invention relates generally to the generation and characterization of anti-MUC18 monoclonal antibodies. The invention further relates to the use of such anti-MUC18 antibodies in the diagnosis and treatment of disorders associated with increased activity of MUC18, in particular, tumors, such as melanomas.
... |
Other Directories (alphabetical): , , , , , , , , , , , , , , , , , , , , -
###
This listing is a sample listing of patents related to Elan for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Elan with additional patents listed. Browse our RSS directory or Search for other possible listings.
|
